Exelixis (EXEL) Loses -11.72% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/08/24
Exelixis (EXEL) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/07/24
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate UpdateBusiness Wire • 02/06/24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in FebruaryBusiness Wire • 02/01/24
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024Business Wire • 01/25/24
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024Business Wire • 01/23/24
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) TabletsBusiness Wire • 01/18/24
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance WoesInvestors Business Daily • 01/08/24
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024Business Wire • 01/07/24
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024Business Wire • 01/02/24
Is the Options Market Predicting a Spike in Exelixis (EXEL) Stock?Zacks Investment Research • 12/12/23